ALung Technologies nabs $36 mln Series C

ALung Technologies Inc, a provider of low-flow extracorporeal carbon dioxide removal technologies that treat patients with acute respiratory failure, has secured $36 million in Series C financing. Philips and UPMC led the round with participation from other investors that included Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures and Riverfront Ventures. Raymond James & Associates was the placement agent.

North AmericaUSBriefs